SDD formula
Phase 2Small molecule
SDD formula is one of 31 small molecule programs targeting Psoriasis Vulgaris. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
30
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
32 competitors in Psoriasis Vulgaris
#DrugCompanyPhaseTrials
1Soriatane
GSKApproved
Rocaltrol
Jazz PharmaceuticalsApproved
Calciferol
Jazz PharmaceuticalsApproved
Otezla
AmgenApproved
Daliresp
AstraZenecaApproved
Prograf
VVeloxis Pharmaceuticals
Approved
Sotyktu
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Acetadote
AArbor Pharmaceuticals, Inc.
Approved
Visudyne
BBausch Health Americas, Inc.
Approved
Lupkynis
Aurinia PharmaceuticalsApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SDD formula. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- CChinese University of Hong Kong